切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2022, Vol. 16 ›› Issue (12) : 1248 -1255. doi: 10.3877/cma.j.issn.1674-0785.2022.12.017

临床研究

诱导阶段加/不加尼妥珠单抗序贯同步放化疗联合尼妥珠单抗治疗局部晚期鼻咽癌的单中心分析
江丹贤1, 曹金鑫1, 杨柳1, 黄静,1   
  1. 1. 524000 广东湛江,广东医科大学附属医院肿瘤科
  • 收稿日期:2022-07-28 出版日期:2022-12-15
  • 通信作者: 黄静

Sequential concurrent chemoradiotherapy with/without nimotuzumab in induction phase combined with nimotuzumab for treatment of locally advanced nasopharyngeal carcinoma: a single-center study

Danxian Jiang1, Jinxin Cao1, Liu Yang1, Jing Huang,1   

  1. 1. Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
  • Received:2022-07-28 Published:2022-12-15
  • Corresponding author: Jing Huang
引用本文:

江丹贤, 曹金鑫, 杨柳, 黄静. 诱导阶段加/不加尼妥珠单抗序贯同步放化疗联合尼妥珠单抗治疗局部晚期鼻咽癌的单中心分析[J/OL]. 中华临床医师杂志(电子版), 2022, 16(12): 1248-1255.

Danxian Jiang, Jinxin Cao, Liu Yang, Jing Huang. Sequential concurrent chemoradiotherapy with/without nimotuzumab in induction phase combined with nimotuzumab for treatment of locally advanced nasopharyngeal carcinoma: a single-center study[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(12): 1248-1255.

目的

探讨诱导阶段加/不加尼妥珠单抗序贯同步放化疗联合尼妥珠单抗治疗局部晚期鼻咽癌的有效性及安全性。

方法

回顾性筛选符合入排标准的2016年5月1日至2021年6月1日广东医科大学附属医院收治的鼻咽癌患者资料,其中在诱导化疗及同步放化疗阶段均联合使用尼妥珠单抗的患者被纳入观察组,共计63例。对照组在同步放化疗阶段联合使用尼妥珠单抗,诱导化疗阶段不使用尼妥珠单抗,共纳入51例。2组患者的基线资料稳定的基础上,对2组患者的疗效进行了统计分析。

结果

观察组的完全缓解(CR)率及1年无进展生存(PFS)率明显优于对照组,2组不良反应无显著差异。

结论

诱导阶段加尼妥珠单抗序贯同步放化疗联合尼妥珠单抗治疗局部晚期鼻咽癌近期疗效好,且未增加毒副作用,安全性好,有临床获益。

Objective

To investigate the effectiveness and safety of sequential concurrent chemoradiotherapy with/without nimotuzumab in the induction phase combined with nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma.

Methods

The data of patients with nasopharyngeal carcinoma admitted to the Affiliated Hospital of Guangdong Medical University from May 1, 2016 to June 1, 2021 who met the inclusion criteria were retrospectively screened, among which patients who were treated with nimotuzumab in both induction chemotherapy and synchronous radiotherapy phases were included in an observation group(63 cases), and those who did not use nimotuzumab in the induction chemotherapy phase were included in a control group(51 cases). The efficacy in the two groups was statistically analyzed on the basis of stable baseline data of the patients.

Results

The complete remission(CR) rate and 1-year progression-free survival(PFS) rate in the observation group were significantly better than those in the control group, and there was no significant difference in adverse effects between the two groups.

Conclusion

Thenimotuzumab containing sequential concurrent chemoradiotherapy in the induction phase combined with nimotuzumab has good short-term efficacy and safety in the treatment of locally advanced nasopharyngeal carcinoma without increased toxic side effects.

表1 2组患者基线特征
对照组n(%)(n=51) 观察组n(%)(n=63) 检验统计量 P
性别 0.456(χ2 0.499
36(70.59) 48(76.19)
15(29.41) 15(23.81)
年龄 1.186(χ2 0.276
<55 35(68.63) 37(58.73)
≥55 16(31.37) 26(41.27)
T分期 6.599(双侧确切概率) 0.084
T1 1(1.96) 6(9.52)
T2 19(37.25) 13(20.63)
T3 16(34.00) 28(34.00)
T4 15(28.30%) 16(25.40%)
N 分期 2.086(双侧确切概率) 0.576
N0 4(7.84%) 5(7.94%)
N1 9(17.65%) 11(17.46%)
N2 26(50.98%) 25(39.68%)
N3 12(23.53%) 22(34.92%)
临床分期 0.052(卡方) 0.852
III 24(49.10%) 31(47.83%)
IVa 27(50.90%) 32(52.17%)
Kps评分 (双侧确切概率) 0.699
<90 4(7.84%) 3(4.35%)
≥90 47(92.16%) 60(95.65%)
BMI 0.106(卡方) 0.745
<18.5 16(31.37%) 18(28.99%)
≥18.5 35(68.63%) 49(71.01%)
诱导化疗 0.518(卡方) 0.564
TPF 29(56.86%) 40(63.77%)
TP 22(43.14%) 23(36.23%)
家族史 (双侧确切概率) 0.222
50(98.04%) 63(91.30%)
1(1.96%) 6(8.70%)
糖尿病 (双侧确切概率) 0.447
50(98.04%) 58(92.06%)
1(1.96%) 5(7.94%)
高血压 (双侧确切概率) 0.655
48(94.12%) 61(96.83%)
3(5.88%) 2(3.17%)
白细胞(/109 7.26(6.17~7.99)a 6.63(5.77~7.97)a -1.202(Z) 0.229
中性粒细胞(/109 4.27(3.55~5.54)a 3.82(3.14~4.89)a -1.681(Z) 0.093
血红蛋白(g/L) 139(126~152)a 140(130~156)a -1.152(Z) 0.249
血小板(/109 251.43±56.41 253.24±54.99 -0.172(T) 0.863
ALT(U/L) 16.8(13.6~27.8)a 18.6(13.9~27.8)a -0.610(Z) 0.542
AST(U/L) 19.8(16.0~24.0)a 18.4(16.1~26.4)a -0.473(Z) 0.636
总胆红素(mmol/L) 9.30(6.60~11.7)a 8.80(6.2~11)a -0.673(Z) 0.501
直接胆红素(mmol/L) 3.10(2.60~4.3)a 3.10(2.4~3.9)a -0.131(Z) 0.896
间接胆红素(mmol/L) 6.20(3.6~8)a 5.4(3.9~7.3)a -0.695(Z) 0.487
白蛋白(g/L) 43.22±4.26 44.71±3.97 -1.926(T) 0.057
肌酐(μmol/L) 72.61±19.15 75.21±15.55 -0.800(T) 0.426
总胆固醇(mmol/L) 4.85(4.2~5.29)a 4.87(4.23~5.63)a -0.735(Z) 0.462
表2 2组患者总体临床疗效比较
表3 2组患者原发灶的临床疗效比较
表4 2组患者颈部淋巴结的临床疗效比较
图1 PFS曲线图
图2 OS曲线图
表5 影响预后的危险因素分析
PFS OS
HR(95% Cl) Wald χ2
P
HR(95% Cl) Wald χ2
P
单因素分析
组别(同步/全程) 0.138(0.017~1.125) 3.42 0.064 0.023(0~4266.33) 0.37 0.541
性别(男/女) 1.259(0.253~6.262) 0.08 0.778 33.063(0~NA) 0.25 0.617
年龄(岁) 1.275(0.303~5.366) 0.11 0.740 0.033(0~55627.447) 0.22 0.641
KPS 21.97(0~NA) 0.21 0.647 21.482(0~NA) 0.02 0.888
BMI 0.629(0.15~2.641) 0.40 0.527 0.195(0.01~3.642) 1.20 0.274
家族史 3.397(0.414~27.88) 1.30 0.255 18.303(1.01~332.43) 3.86 0.049
高血压 0.046(0~302795.76) 0.15 0.701 0.049(0~NA) 0.01 0.936
糖尿病 0.049(0~NA) 0.04 0.838 0.049(0~NA) 0.01 0.936
T期(T1/T2/T3/T4 1.219(0.548~2.711) 0.24 0.627 0.821(0.169~3.991) 0.06 0.806
N期(N0/N1/N2/N3 0.91(0.429~1.932) 0.06 0.806 0.391(0.086~1.775) 1.48 0.224
临床分期(III/IV) 1.508(0.36~6.312) 0.32 0.574 0.413(0.023~7.563) 0.36 0.551
诱导化疗(TPF/TP) 1.818(0.366~9.024) 0.53 0.465 58.334(0~NA) 0.47 0.495
白细胞 1.202(0.922~1.568) 1.85 0.173 1.311(0.826~2.083) 1.32 0.251
中性粒细胞 1.35(1.055~1.727) 5.68 0.017 1.353(0.874~2.093) 1.84 0.175
血红蛋白 0.987(0.971~1.003) 2.74 0.098 0.973(0.943~1.005) 2.75 0.097
血小板 1.009(0.997~1.022) 2.11 0.146 1.015(0.989~1.042) 1.23 0.268
ALT 0.998(0.982~1.015) 0.06 0.809 1.001(0.979~1.022) 0.00 0.994
AST 0.987(0.924~1.054) 0.16 0.692 1.005(0.959~1.054) 0.05 0.824
总胆红素 0.867(0.704~1.066) 1.83 0.176 0.801(0.505~1.272) 0.88 0.348
直接胆红素 0.825(0.451~1.509) 0.39 0.531 0.900(0.458~1.769) 0.09 0.760
间接胆红素 0.788(0.59~1.053) 2.59 0.108 0.601(0.265~1.367) 1.47 0.225
白蛋白 0.779(0.662~0.918) 8.94 0.003 0.535(0.26~1.103) 2.87 0.090
肌酐 0.997(0.956~1.04) 0.02 0.884 1.024(0.965~1.087) 0.62 0.431
总胆固醇 0.454(0.246~0.839) 6.35 0.012 0.052(0.002~1.46) 3.02 0.082
多因素分析
家族史 2.979(0.331~26.80) 0.95 0.330 100663.987(0~NA) 0.02 0.897
中性粒细胞 1.205(0.924~1.57) 1.89 0.169 1.233(0~NA) 0.00 0.989
白蛋白 0.812(0.68~0.97) 5.27 0.022 0.253(0~178905.56) 0.04 0.842
总胆固醇 0.534(0.256~1.115) 2.79 0.095 0.07(0~5.433E+54) 0.00 0.968
表6 不良反应总结
1
Kanno M, Narita N, Fujimoto Y, et al. Third Epidemiological Analysis of Nasopharyngeal Carcinoma in the Central Region of Japan from 2006 to 2015 [J]. Cancers(Basel), 2019, 11(8): 1180.
2
Wu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates [J]. Exp Ther Med, 2018, 15(4): 3687-3692.
3
Hennessy MA, Morris PG. Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: triplet or doublet chemotherapy?[J]. Anticancer Drugs, 2020, 31(2): 97-100.
4
Airoldi M, Gabriele AM, Garzaro M, et al. Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population [J]. Radiother Oncol, 2009, 92(1): 105-110.
5
Zhou R, Zhu J, Chen X, et al. The efficacy and safety of docetaxel, cisplatin and fluorouracil(TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis [J]. Clin Transl Oncol, 2020, 22(3): 429-439.
6
Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy [J]. Int J Radiat Oncol Biol Phys, 2004, 59(1): 11-20.
7
Bourouba M, Benyelles-Boufennara A, Terki N, et al. Epidermal growth factor receptor(EGFR) abundance correlates with p53 and Bcl-2 accumulation and patient age in a small cohort of North African nasopharyngeal carcinoma patients [J]. Eur Cytokine Netw, 2011, 22(1): 38-44.
8
Cripps C, Winquist E, Devries MC, et al. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer [J]. Curr Oncol, 2010, 17(3): 37-48.
9
Xu T, Ou X, Shen C, et al. Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma [J]. Anticancer Drugs, 2016, 27(1): 66-70.
10
Wang F, Jiang C, Ye Z, et al. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma [J]. Oncotarget, 2017, 8(43): 75544-75556.
11
Lin M, You R, Liu YP, et al. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma [J]. Oral Oncol, 2018, 80: 1-8.
12
You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage Ⅱ-Ⅳb nasopharyngeal carcinoma [J]. Int J Cancer, 2017, 141(6): 1265-1276.
13
Bar-Ad V, Zhang QE, Harari PM, et al. Correlation between the severity of cetuximab-induced skin rash and clinical outcome for head and neck cancer patients: The RTOG experience [J]. Int J Radiat Oncol Biol Phys, 2016, 95(5): 1346-1354.
14
Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage Ⅲ to Ⅳ head and neck carcinoma: RTOG 0522 [J]. J Clin Oncol, 2014, 32(27): 2940-2950.
15
Allen PJ, Kuk D, Castillo CF, et al. Multi-institutional validation study of the American Joint Commission on Cancer(8th Edition) changes for T and N staging in patients With pancreatic adenocarcinoma [J]. Ann Surg, 2017, 265(1): 185-191.
16
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1) [J]. Eur J Cancer, 2009, 45(2): 228-247.
17
Lin M, Yang Q, Zou X, et al. Biopsy of distant metastasis is not a significant prognostic factor for synchronous metastatic nasopharyngeal carcinoma: a propensity score-matched analysis from the Surveillance Epidemiology and End-Results Registry [J]. J Cancer, 2021, 12(14): 4424-4432.
18
Yang XL, Wang Y, Bao Y, et al. Additional cervical lymph node biopsy is not a significant prognostic factor for nasopharyngeal carcinoma in the intensity-modulated radiation therapy era: A propensity score-matched analysis from an epidemic area [J]. J Cancer, 2018, 9(16): 2844-2851.
19
Yao JJ, Zhang LL, Gao TS, et al. Comparing treatment outcomes of concurrent chemoradiotherapy with or without nimotuzumab in patients with locoregionally advanced nasopharyngeal carcinoma [J]. Cancer Biol Ther, 2018, 19(12): 1102-1107.
20
Fangzheng W, Chuner J, Zhiming Y, et al. Long-term use of nimotuzumab in combination with intensity-modulated radiotherapy and chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma: Experience of a single institution [J]. Oncol Res, 2018, 26(2): 277-287.
21
Kong L, Zhang Y, Hu C, et al. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage Ⅲ or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials [J]. Cancer, 2017, 123(12): 2258-2267.
22
Sun Y, Li WF, Chen NY, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial [J]. Lancet Oncol, 2016, 17(11): 1509-1520.
23
Lin JC, Jan JS, Hsu CY, et al. Phase Ⅲ study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival [J]. J Clin Oncol, 2003, 21(4): 631-637.
24
Li XY, Chen QY, Sun XS, et al. Ten-year outcomes of survival and toxicity for a phase Ⅲ randomised trial of concurrent chemoradiotherapy versus radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma [J]. Eur J Cancer, 2019, 110: 24-31.
[1] 张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性:单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 聂生军, 王钰, 王毅, 鲜小庆, 马生成. 复方倍他米松局部注射联合光动力疗法治疗小型瘢痕疙瘩的临床疗效观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 404-410.
[4] 莫淇舟, 苏劲, 黄健, 李健维, 李思宁, 柳建军. 智能控压输尿管软镜碎石吸引取石术在直径10~25 mm上尿路结石中的应用[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 497-502.
[5] 李义亮, 苏拉依曼·牙库甫, 麦麦提艾力·麦麦提明, 克力木·阿不都热依木. 机器人与腹腔镜食管裂孔疝修补术联合Nissen 胃底折叠术短期疗效分析[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 512-517.
[6] 周艳, 李盈, 周小兵, 程发辉, 何恒正. 不同类型补片联合Nissen 胃底折叠术修补食管裂孔疝的疗效及复发潜在危险因素[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 528-533.
[7] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[8] 詹济玮, 蔡柳春, 温琼娜, 郭石生, 温春妹, 温鹤明. 布地格福联合噻托溴铵治疗AECOPD 的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 823-826.
[9] 王亚岚, 倪婧, 余世庆, 陶银花, 张荣. 尼达尼布抗纤维化治疗特发性肺纤维化的耐受性和疗效预测因素分析[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 750-755.
[10] 魏孔源, 仵正, 王铮, 黎韡. 机器人胰腺中段切除后远端胰腺消化道不同重建方式初探[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 295-300.
[11] 梁艳娉, 列诗韵, 王艺穗, 吴晓瑛, 林颖. 基于内镜操作细节记录系统构建胃底静脉曲张内镜下组织胶注射术的标准化管理方案[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 705-709.
[12] 陈杰, 武明胜, 李一金, 李虎, 向源楚, 荣新奇, 彭健. 低位直肠癌冷冻治疗临床初步分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 494-498.
[13] 史彬, 司远. 益气和络方联合缬沙坦治疗气阴两虚兼血瘀证IgA 肾病的疗效观察[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 306-312.
[14] 韩俊岭, 王刚, 马厉英, 连颖, 徐慧. 维生素D 联合匹维溴铵治疗腹泻型肠易激综合征患者疗效及对肠道屏障功能指标的影响研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 560-564.
[15] 阳跃, 庹晓晔, 崔子豪, 欧阳四民, 林海阳, 胡景宇, 胡银, 李涛, 赵景峰, 郝岱峰, 冯光. 改良“阅读者”皮瓣修复骶尾部压疮的疗效[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 751-755.
阅读次数
全文
9
HTML PDF
最新录用 在线预览 正式出版 最新录用 在线预览 正式出版
0 0 1 0 0 8

  来源 本网站 其他网站
  次数 6 3
  比例 67% 33%

摘要
68
最新录用 在线预览 正式出版
0 0 68
  来源 本网站 其他网站
  次数 30 38
  比例 44% 56%